Bluebird Bio could be acquired by end of 2016, possibly at value of around USD 10bn
Bluebird Bio (NASDAQ: BLUE), a Cambridge, Massachusetts-based gene therapeutics company, could be acquired by the end of 2016, according to comments by a biotech investor in The Energy Report's Life Sciences Report.
The report cited Ran Nussbaum, managing partner with The Pontifax Group, saying that among gene therapy companies he believed Bluebird had a solid core business, so he doubted "big pharmas" would let Bluebird stay an independent business.
He also stated that he believed the company could become bigger, and that while its recent market cap has been around USD 4.8bn, he could see it selling for about USD 10bn.
Energy Report
--> BLUE US has a market cap of $4.6bil...offer nice upside